DSM-Firmenich Q3 adjusted EBITDA reaches €483 million
Adjusted EBITDA was €483 million, versus DSM-provided consensus of €478 million.
Related stories
Lal PathLabs Reports September-Quarter Consolidated Net Profit of 1.92 Billion Rupees
M impact | EARNINGS | Nov 04, 2026, 07:59 AM UTC
Marksans Pharma September-Quarter Revenue From Operations at 9.40 Billion Rupees
M impact | EARNINGS | Nov 04, 2026, 07:58 AM UTC
Marksans Pharma Reports September-Quarter Consolidated Net Profit of 1.41 Billion Rupees
M impact | EARNINGS | Nov 04, 2026, 07:58 AM UTC
Pandora Raises 2026 Targets on Demand for New Products
Pandora raised its 2026 targets, supported by demand for new products.
M impact | EARNINGS | Nov 04, 2026, 07:58 AM UTC
Magle Chemoswed Reports Q3 Sales of SEK 70.9 Million
M impact | EARNINGS | Nov 04, 2026, 07:56 AM UTC
Magle Chemoswed Q3 EBITDA SEK -31.1 million
M impact | EARNINGS | Nov 04, 2026, 07:56 AM UTC